Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer
Clinical trial NCT06229067 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06229067
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-01-19
- Primary completion
- 2025-01-19
- Enrollment
- 182
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.